|
|
|
| Effects of low-dose Simvastatin on serum complement system in patients with cardiorenal syndrome |
| WANG Zhi HUANG Jin▲ LI Yimin YAN Xuejiao |
| Department of Cardiology, Nanjing Chest Hospital, Jiangsu Province, Nanjing 210029, China |
|
|
|
Abstract Objective To investigate the effects of low-dose Simvastatin on serum levels of C3, C4 and mRNA levels of type Ⅰ (CR1) and Ⅱ (CR2) complement receptor in patients with cardiorenal syndrome (CRS). Methods Totally 56 patients with CRS were enrolled from January to December in 2012 and treated with Simvastatin (10 mg once per night) for 8 weeks. The serum levels of C3 and C4 were measured. Peripheral blood mononuclear cells were extracted from patients before and after treatment with Simvastatin. RT-PCR was performed to detect the mRNA expression of CR1 and CR2. The left ventricular ejection fraction was determined by Doppler spectrum analysis. Results After therapy, the mean levels of serum C3 was significantly decreased in patients with CRS [(1.14±0.35) vs (1.22±0.31) g/L, P < 0.05]. Contrarily, the mean mRNA level of CR1 increased after therapy (0.76±0.10 vs 0.70±0.11, P < 0.05). Conclusion The down-regulation of serum level of C3 as well as up-regulation of CR1 after treatment with low-dose Simvastatin is probably associated with improvement of heart and renal function in patients with CRS.
|
|
|
|
|
|
[1] 中华医学会心血管病学分会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志，2014，42（2）：98-122.
[2] Bock JS，Gottlieb SS. Cardiorenal syndrome：new perspectives [J]. Circulation，2010，121：2592-2600.
[3] Shah HR，Singh NP，Aggarwal NP，et al. Cardiorenal syndrome：clinical outcome study [J]. J Assoc Physicians India，2016，64（12）：41-46.
[4] Ronco C，Di Lullo L. Cardiorenal syndrome in western countries：epidemiology，diagnosis and management approaches [J]. Kidney Dis（Basel），2017，2（4）：151-163.
[5] 王治，严虹，黄进.小剂量辛伐他汀对心肾综合征患者心、肾功能的影响[J].中国医药导报，2015，12（23）：138-141.
[6] 刘春笑.辛伐他汀治疗高血压合并2型糖尿病的临床效果[J].中国当代医药，2015，22（27）：105-106，109.
[7] 张辉，殷力，张雁儒，等.辛伐他汀预防激素性股骨头坏死的实验研究[J].中国当代医药，2016，23（2）：11-13，17.
[8] 刘青建.辛伐他汀对脑梗死患者脑源性神经营养因子水平的影响[J].中国当代医药，2016，23（5）：128-130.
[9] Ronco C，Ronco F. Cardio-renal syndromes：a systematic approach for consensus definition and classification [J]. Heart Fail Rev，2012，17（2）：151-160.
[10] Yancy CW，Jessup M，Bozkurt B，et al. 2013 ACCF/AHA guideline for the management of heart failure：a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [J]. J Am Coll Cardiol，2013，62（16）：e147-e239.
[11] Fu Q，Cao L，Li H，et al. Cardiorenal syndrome：pathophysiological mechanism，preclinical models，novel contributors and potential therapies [J]. Chin Med J（Engl），2014，127（16）：3011-3018.
[12] 王治，黄进.神经调节蛋白1诱导小鼠胚胎干细胞向心肌细胞的分化及其机制探讨[J].中国组织工程研究与临床康复，2011，15（32）：5957-5961.
[13] Zhang J，Bottiglieri T，McCullough PA. The central role of endothelial dysfunction in cardiorenal syndrome [J]. Cardiorenal Med，2017，7（2）：104-117.
[14] Matsushita K. Pathogenetic pathways of cardiorenal syndrome and their possible therapeutic implications [J]. Curr Pharm Des，2016，22（30）：4629-4637.
[15] Preeti J，Alexandre M，Pupalan I，et al. Chronic heart failure and comorbid renal dysfunction-a focus on type 2 cardiorenal syndrome [J]. Curr Cardiol Rev，2016，12（3）：186-194.
[16] Torre-Amione G. Immune activation in chronic heart failure [J]. Am J Cardiol，2005，95（11A）：3C-8C.
[17] Yagi S，Aihara K，Ikeda Y，et al. Effects of statins on cardiorenal syndrome [J]. Int J Vasc Med，2012，2012：162545.
[18] Niculescu F，Rus H. Complement activation and atherosclerosis [J]. Mol Immunol，1999，36（13-14）：949-955.
[19] Iacoviello M，Monitillo F，Leone M，et al. The renal arterial resistance index predicts worsening renal function in chronic heart failure patients [J]. Cardiorenal Med，2016， 7（1）：42-49.
[20] Ghebrehiwet B. The complement system：an evolution in progress [J]. F1000Res，2016，5：2840.
[21] Clark DJ，Cleman MW，Pfau SE，et al. Serum complement activation in congestive heart failure [J]. Am Heart J，2001，141（4）：684-690.
[22] Hovland A，Jonasson L，Garred P，et al. The complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosis [J]. Atherosclerosis，2015，241（2）：480-494.
[23] Farrar CA，Zhou W，Lin T，et al. Local extravascular pool of C3 is a determinant of postischemic acute renal failure [J]. FASEB J，2006，20：217-226.
[24] Kelly KJ，Liu Y，Zhang J，et al. Renal C3 complement component：feed forward to diabetic kidney disease [J]. Am J Nephrol，2015，41（1）：48-56.
[25] Java A，Liszewski MK，Hourcade DE，et al. Role of complement receptor1（CR1；CD35）on epithelial cells：a model for understanding complement-mediated damage in the kidney [J]. Mol Immunol，2015，67（200）：584-595. |
|
|
|
